Amicus Therapeutics gets grant for treatment of fabry disease with migalastat for specific mutations

4d ago, source: Pharmaceutical Technology

Discover Amicus Therapeutics' groundbreaking patent for treating Fabry disease with migalastat, targeting specific mutations in a-galactosidase A. Learn about the innovative method and potential ...

Amicus Therapeutics Inc (FOLD) Stock: A Value Analysis

6mon ago, source: newsheater

Based on Amicus Therapeutics Inc (FOLD), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at -0.17. The debt to equity ratio ...

Wave of Amicus Briefs Back Drug Price Plan at Trial Court Stage

2d ago, source:

The Biden administration’s efforts to fend off legal challenges from the pharmaceutical industry battling Medicare drug price ...

Interview with the President and CEO: BioVie Inc. (NASDAQ:BIVI)

10d ago, source: The Wall Street Transcript

Let’s start with a brief overview and history of the company. Mr. Do: BioVie was started by Jonathan Adams to develop a drug called terlipressin to treat ascites, which is end stage liver disease. I ...

Takeda said to have left industry trade group BIO

on MSN ago, source:

Takeda Pharmaceutical (TAK) joins Pfizer (PFE) in leaving the Biotechnology Innovation Organization, the top biotech lobbying ...

Life Sciences Funds’ Improving Health

12d ago, source: Institutional Investor

March was another profitable month for life sciences and biopharma hedge funds.

Avenue Therapeutics Announces Reverse Stock Split

4d ago, source:

The reverse stock split was approved on March 6, 2024 by Avenue’s Board of Directors and stockholders representing approximately 56% of the voting power of Avenue’s outstanding capital stock, with the ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 Earnings Call Transcript

on MSN ago, source:

Q1 2024 Earnings Call Transcript April 24, 2024 Viking Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.26 ...

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

3d ago, source: Business Wire

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company ...

As more rare disease therapies launch, their prices are rising

on MSN ago, source:

Rare disease therapies are extremely expensive, with some costing millions of dollars. They are getting even more pricey.

PTC Therapeutics: A Balanced Hold Rating Amid Regulatory Challenges and Upcoming Milestones

2d ago, source:

PTC Therapeutics (PTCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jeffrey ...

Amicus Curiae Focuses on Harlan

10d ago, source: Marshall Parthenon

It takes immense courage to be a stand-alone national judge, an editor said in the final Amicus Curiae lecture of the ...